Poster DMT53

Tanuja Chitnis | tchitnis@bwh.harvard.edu

Remibrutinib, a Highly Selective and Potent BTKi in Development for MS, Did Not Impact Serum Immunoglobulin Levels: Insights From Chronic Spontaneous Urticaria

Robert Bermel,[1] Warner Carr,[2] Tanuja Chitnis,[3] Thomas Dörner,[4] Koremasa Hayama,[5] Michihiro Hide,[6] Marcus Maurer,[7,8] Xavier Montalban,[9] Gordon Sussman,[10] Heinz Wiendl,[11] Swapnil Dahale,[12] Virginia DeLasHeras,[13] Sibylle Haemmerle,[13] Bernd C. Kieseier,[13] Karine Lheritier,[13] Artem Zharkov,[13] Roman Willi,[13] Ana Giménez-Arnau[14]

[1]Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA; [2]Allergy and Asthma Associates of Southern California, and Southern California Research, Mission Viejo, CA, USA; [3]Department of Neurology, Brigham and Women's Hospital, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA; [4]Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany; [5]Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan; [6]Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; [7]Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; [8]Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany; [9]Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain; [10]University of Toronto, Toronto, Ontario, Canada; [11]Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany; [12]IQVIA, Mumbai, India; [13]Novartis Pharma AG, Basel, Switzerland; [14]Department of Dermatology, Hospital del Mar – IMIM, Universitat Pompeu Fabra, Barcelona, Spain

KEY FINDINGS & CONCLUSIONS

- Remibrutinib treatment had no meaningful impact on total mean immunoglobulin levels in participants with chronic spontaneous urticaria in phase 2 studies, including those who received long-term treatment up to 52 weeks with 100 mg twice daily, the dose used in multiple sclerosis clinical trials
- Exposure-adjusted incidence rates of infections did not increase in the extension study and remained comparable to any remibrutinib/placebo arm in the core study
- The results of these analyses are in line with the favorable safety profile observed with remibrutinib across immune-mediated diseases so far to date

Scan to obtain a copy of the poster

https://bit.ly/CMSCDMT53

This study was sponsored by Novartis Pharma AG, Basel, Switzerland

Poster presented at the Consortium of Multiple Sclerosis Centers (CMSC) 38th Annual Meeting • May 29-June 1, 2024 • Nashville, TN, USA

Previously presented at AAN Annual Meeting • April 13-18, 2024 • Denver, CO, USA; and AAAI Conference • February 20-27, 2024 • Vancouver, BC, Canada

INTRODUCTION

- Remibrutinib is a novel, highly selective and potent, covalent, oral Bruton's tyrosine kinase inhibitor that downregulates myeloid and B-cell activation without depleting B cells[1,2]
- The ongoing remibrutinib clinical development program comprises >25 studies, with >2900 subjects exposed to remibrutinib at doses up to 600 mg/day and duration of up to 52 weeks[3]
- Remibrutinib has demonstrated efficacy with a favorable safety profile for up to 52 weeks, including with 100 mg twice daily (BID) dose in the phase 2b core and extension studies (NCT03926611 and NCT04109313, respectively) and in the 24-week primary analysis of the phase 3 studies (REMIX-1: NCT05030311; REMIX-2: NCT05032157) in patients with chronic spontaneous urticaria (CSU)[4-7]
- Remibrutinib is currently being evaluated in two pivotal phase 3 trials in multiple sclerosis (MS), REMODEL-1 (NCT05147220) and REMODEL-2 (NCT05156281), designed to establish the therapeutic potential of remibrutinib as a novel treatment in relapsing MS (RMS)[8]

OBJECTIVES

- To assess the mean serum immunoglobulin (Ig) levels and incidence rates of infections over time in a phase 2b core and extension study of remibrutinib in CSU, including with 100 mg BID, the dosing regimen being evaluated in the phase 3 trials in RMS

METHODS

Study Design and Patients

- The phase 2b core study was a dose-finding, multicenter, randomized, double-blind, placebo-controlled study conducted across 17 countries in patients with CSU[4] (**Figure 1**)

Study Assessments and Statistical Analyses

- Total mean serum immunoglobulin G (IgG) and immunoglobulin M (IgM) levels were assessed at baseline and Week 12 during the core study and at baseline, Week 28, and Week 52 during the extension study
- Exposure-adjusted incidence rates (EAIR) for infections (events per 100 patient-years) and Ig levels were analyzed using summary statistics based on the safety set

Figure 1. Study Design[a]



[a]Further details on the study design are provided in references 4 and 5
BID, twice daily; N, total number of patients; n, number of patients included in each group; QD, once daily; R, randomization; UAS7, weekly Urticaria Activity Score

RESULTS

- Of the 309 patients included in the phase 2b core study, 194 patients who rolled over to the 52-week extension study were included in the analysis
- Patient demographics, baseline disease characteristics, and mean serum IgG and IgM levels were comparable between groups in the core study and across core and extension studies (**Table 1**)
- Exposure-adjusted incidence rates of infections did not increase with long-term exposure to remibrutinib treatment (**Table 2**)

Table 1. Patient Demographics and Baseline Disease Characteristics (Safety Set)

	Core study		Extension study
Characteristics	**Any remibrutinib arm (N=267)**	**Placebo (N=42)**	**Remibrutinib 100 mg BID (N=194)**
Age, years	45.1 (14.8)	44.8 (15.3)	45.5 (14.1)
Female, n (%)	197 (73.8)	24 (57.1)	139 (71.6)
BMI, kg/m²	28.1 (6.1)	27.2 (6.4)	28.1 (6.2)
Baseline serum Ig levels			
IgG, g/L	10.9 (2.4)	10.8 (2.6)	11.0 (2.4)
IgM, g/L	1.2 (0.9)	1.1 (0.7)	1.0 (0.8)

Data are presented as mean (SD), unless stated otherwise
BID, twice daily; BMI, body mass index; Ig, immunoglobulin; IgG, immunoglobulin G; IgM, immunoglobulin M; N, total number of patients in each arm

Table 2. Infection Rates (EAIR) in the Core and Extension Studies (Safety Set)

	Core study		Extension study
Characteristics	**Any remibrutinib arm (N=267)**	**Placebo (N=42)**	**Remibrutinib 100 mg BID (N=194)**
Infection rates, EAIR (95% CI)	107.7 (83.5-136.8)	98.7 (45.1-187.3)	40.3 (30.9-51.8)

Infections were defined as MedDRA SOC infections and infestations
BID, twice daily; EAIR, exposure-adjusted incidence rate; MedDRA, Medical Dictionary for Regulatory Activities; N, total number of patients; SOC, System Organ Class

- No meaningful change from baseline in the total mean serum IgG and IgM levels in any remibrutinib arm (any dose) was observed at Week 12 in the core study or Weeks 28 and 52 in the extension study with 100 mg BID (**Figure 2**)

Figure 2. Mean Serum IgG and IgM Levels in the Core Study (A, C) and the Extension Study (B, D; Safety Set) in the Remibrutinib and Placebo Arms



represents the normal range of serum Ig levels
BID, twice daily; Ig, immunoglobulin; IgG, immunoglobulin G; IgM, immunoglobulin M; n, number of patients evaluated in each arm; W, Week

References

1. Angst D et al. *J Med Chem.* 2020;63(10):5102-5118. **2.** Pulz R et al. Poster presented at: *ECTRIMS 2022*; EPO0896. **3.** Data on file. Investigator brochure. Novartis Pharma AG; March 10, 2024. **4.** Maurer M et al. *J Allergy Clin Immunol.* 2022;150(6):1498-1506.e2. **5.** Jain V et al. *J Allergy Clin Immunol.* 2023;S0091-6749.901346-5. **6.** Saini S et al. Oral presentation at: *ACAAI* 2023; LB001. **7.** McDonald C et al. *Immunology.* 2021;164(4):722-736. **8.** Wiendl H et al. Poster presented at: *ECF* 2023; P44.

Acknowledgments

Medical writing support was provided by Bhavesh Kshirsagar and Sreelatha Komatireddy and design support by Hareesh Cheela, employees of Novartis Corporate Center, Hyderabad, India. Editorial assistance for this poster was provided by Envision Pharma Group and was funded by Novartis Pharmaceuticals Corporation. The final responsibility for the content lies with the authors

Disclosures

Robert Bermel has served as a consultant for AstraZeneca, Biogen, EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme, TG Therapeutics, and VielaBio; has received research support from Biogen, Genentech, and Novartis; and shares rights to intellectual property underlying the Multiple Sclerosis Performance Test, currently licensed to Qr8 Health and Biogen. **Warner Carr** is a speaker or consultant for Aluna, Amgen, AstraZeneca, DBV, MERZ, Optinose, Regeneron, Sanofi, and Teva. **Tanuja Chitnis** has received compensation for consulting from Biogen, Novartis, Roche/Genentech, and Sanofi-Genzyme and has received research support from Brainstorm Cell Therapeutics, EMD Serono, I-Mab Biopharma, Mallinckrodt ARD, the National Institutes of Health, the National MS Society, Novartis Pharmaceuticals, Octave Bioscience, Roche/Genentech, the Sumaira Foundation, Tiziana Life Sciences, and the US Department of Defense. **Thomas Dörner** has been an advisor or a review panel member of AbbVie, Bristol Myers Squibb, Eli Lilly and Company, Novartis, and UCB; has received grant/research support from AbbVie, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Novartis, Roche/Genentech, and UCB; and has received speaker fees/honoraria from Janssen. **Koremasa Hayama** was a speaker and/or advisor for and/or has received research funding from AbbVie, Boehringer Ingelheim, Eisai, Janssen, Kaken, Kyorin, Kyowa Kirin, Maruho, Mitsubishi Tanabe, Nihon, Novartis, Sanofi, Sun Pharma, and Taiho. **Michihiro Hide** has received lecture and/or consultation fees from GI Innovation, Kaken, Kyowa Kirin, Merck, Mitsubishi Tanabe, Novartis, Sanofi, Taiho, Teikoku Seiyaku, and Uriach. **Marcus Maurer** is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Amgen, Aralez, argenx, AstraZeneca, Celldex, Centogene, CSL Behring, Eli Lilly and Company, Faes, Genentech, GI Innovation, Innate Pharma, Kyowa Kirin, LEO Pharma, Menarini, Moxie, Novartis, Roche, Sanofi/Regeneron, Third Harmonic Bio, UCB, and Uriach. **Xavier Montalban** has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials, or has participated in advisory boards of clinical trials in the past years with AbbVie, Actelion, Alexion, Bayer, Biogen, Bristol Myers Squibb/Celgene, EMD Serono, Excemed, F. Hoffmann-La Roche, Genzyme, Immunic, Janssen, Medday, Merck, the MS International Federation, Mylan, the National MS Society, Nervgen, Novartis, Sandoz, Sanofi-Genzyme, Teva, and TG Therapeutics. **Gordon Sussman** has received research support from Aimmune, ALK, Amgen, AstraZeneca, DBV, Genentech, Kedrion, LEO Pharma, Merck, Novartis, Nuvo, Regeneron, Sanofi, Schering Plough, and Stallergenes and is a medical advisor and/or has received payment for lectures from the Allergy Asthma and Immunology Society of Ontario, Anaphylaxis Canada, the Canadian Hereditary Angioedema Network, CSL Behring, Merck, Novartis, and Pfizer. **Heinz Wiendl** has received honoraria for acting as a member of scientific advisory boards for Janssen, Merck, and Novartis; has received speaker honoraria and travel support from Alexion, Amicus, Biogen, Biologix, Bristol Myers Squibb, Cognomed, F. Hoffmann-La Roche, Gemeinnützige Hertie-Stiftung, Genzyme, Medison, Merck, Novartis, Roche Pharma AG, Teva, and WebMD Global; is a paid consultant for Biogen, Bristol Myers Squibb, EMD Serono, Idorsia, Immunic, Immunovant, Janssen, Johnson & Johnson, Novartis, Roche, Sanofi, the Swiss Multiple Sclerosis Society, and UCB; and his research is funded by Alexion, Amicus, argenx, Biogen, CSL Behring, Deutsche Forschungsgesellschaft (DFG), Deutsche Myasthenie Gesellschaft e.V., F. Hoffmann-La Roche, the German Ministry for Education and Research (BMBF), Genzyme, Merck KgaA, Novartis Pharma, Roche, and UCB. **Swapnil Dahale** is an employee of IQVIA. **Virginia DeLasHeras**, **Sibylle Haemmerle**, **Bernd Kieseier**, **Karine Lheritier**, **Artem Zharkov**, and **Roman Willi** are employees of Novartis. **Ana Giménez-Arnau** reports roles as a medical advisor for Amgen, Faes, Genentech, GlaxoSmithKline, Novartis, Sanofi, Thermo Fisher Scientific, and Uriach; has research grants supported by Instituto Carlos III-FEDER, Novartis, and Uriach; and participates in educational activities for Almirall, Avene, Genentech, GlaxoSmithKline, Novartis, LEO Pharma, Menarini, Merck, and Sanofi, and Uriach